Booth Bruce sold KYMR

March 2, 2026 · Form 4 insider transaction

Booth Bruce sold 71,814 shares of Kymera Therapeutics, Inc. at $90.13 per share, a transaction worth $6.47M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
71,814
Price
$90.13
Total value
$6.47M
RoleDirector
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateMarch 2, 2026
Filing dateMarch 4, 2026
Shares owned after3,902,667
OwnershipIndirect
10b5-1 planYes
AmendedNo

Footnotes

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.05 to $90.441 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote.; These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.

View the original Form 4 on SEC EDGAR